Clinical Trial

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Study acronym: Opti-GAIN
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2026-02-04; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT07392255
Lead Sponsor Complement Therapeutics
Conditions Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment 75 participants
Start Date 2025-12-30
Primary Completion 2028-05-31 (estimated)
Study Completion 2032-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-22